317 related articles for article (PubMed ID: 26855777)
21. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.
Rogliani P; Matera MG; Page C; Puxeddu E; Cazzola M; Calzetta L
Respir Res; 2019 May; 20(1):104. PubMed ID: 31133026
[TBL] [Abstract][Full Text] [Related]
22. Effect of N-acetyl cysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue.
Bridgeman MM; Marsden M; Selby C; Morrison D; MacNee W
Thorax; 1994 Jul; 49(7):670-5. PubMed ID: 8066561
[TBL] [Abstract][Full Text] [Related]
23. Antioxidant therapies in COPD.
Rahman I
Int J Chron Obstruct Pulmon Dis; 2006; 1(1):15-29. PubMed ID: 18046899
[TBL] [Abstract][Full Text] [Related]
24. Antioxidant and pro-oxidant effect of the thiolic compounds N-acetyl-L-cysteine and glutathione against free radical-induced lipid peroxidation.
Sagristá ML; García AE; Africa De Madariaga M; Mora M
Free Radic Res; 2002 Mar; 36(3):329-40. PubMed ID: 12071352
[TBL] [Abstract][Full Text] [Related]
25. N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation.
Calzetta L; Rogliani P; Facciolo F; Rinaldi B; Cazzola M; Matera MG
Biomed Pharmacother; 2018 Jul; 103():1-8. PubMed ID: 29635121
[TBL] [Abstract][Full Text] [Related]
26. Oxidants/antioxidants and COPD.
MacNee W
Chest; 2000 May; 117(5 Suppl 1):303S-17S. PubMed ID: 10843965
[TBL] [Abstract][Full Text] [Related]
27. Oxidants in asthma and in chronic obstructive pulmonary disease (COPD).
Psarras S; Caramori G; Contoli M; Papadopoulos N; Papi A
Curr Pharm Des; 2005; 11(16):2053-62. PubMed ID: 15974958
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological and dietary antioxidant therapies for chronic obstructive pulmonary disease.
Biswas S; Hwang JW; Kirkham PA; Rahman I
Curr Med Chem; 2013; 20(12):1496-530. PubMed ID: 22963552
[TBL] [Abstract][Full Text] [Related]
29. Antioxidant therapeutic advances in COPD.
Rahman I
Ther Adv Respir Dis; 2008 Dec; 2(6):351-74. PubMed ID: 19124382
[TBL] [Abstract][Full Text] [Related]
30. Repeated-Dose Oral N-Acetylcysteine in Parkinson's Disease: Pharmacokinetics and Effect on Brain Glutathione and Oxidative Stress.
Coles LD; Tuite PJ; Öz G; Mishra UR; Kartha RV; Sullivan KM; Cloyd JC; Terpstra M
J Clin Pharmacol; 2018 Feb; 58(2):158-167. PubMed ID: 28940353
[TBL] [Abstract][Full Text] [Related]
31. Long-term oral n-acetylcysteine reduces exhaled hydrogen peroxide in stable COPD.
De Benedetto F; Aceto A; Dragani B; Spacone A; Formisano S; Pela R; Donner CF; Sanguinetti CM
Pulm Pharmacol Ther; 2005; 18(1):41-7. PubMed ID: 15607126
[TBL] [Abstract][Full Text] [Related]
32. N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD.
Pela R; Calcagni AM; Subiaco S; Isidori P; Tubaldi A; Sanguinetti CM
Respiration; 1999; 66(6):495-500. PubMed ID: 10575333
[TBL] [Abstract][Full Text] [Related]
33. The effect of diesel emission exposure on primary human bronchial epithelial cells from a COPD cohort: N-acetylcysteine as a potential protective intervention.
Vaughan A; Stevanovic S; Jafari M; Rahman M; Bowman RV; Fong KM; Ristovski Z; Yang IA
Environ Res; 2019 Mar; 170():194-202. PubMed ID: 30590262
[TBL] [Abstract][Full Text] [Related]
34. Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD.
Tse HN; Raiteri L; Wong KY; Ng LY; Yee KS; Tseng CZS
Chest; 2014 Sep; 146(3):611-623. PubMed ID: 24833327
[TBL] [Abstract][Full Text] [Related]
35. High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON Study.
Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Xia QK; Gao Y; Zhong NS;
COPD; 2013 Apr; 10(2):164-71. PubMed ID: 23061828
[TBL] [Abstract][Full Text] [Related]
36. N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why.
Aldini G; Altomare A; Baron G; Vistoli G; Carini M; Borsani L; Sergio F
Free Radic Res; 2018 Jul; 52(7):751-762. PubMed ID: 29742938
[TBL] [Abstract][Full Text] [Related]
37. N-Acetylcysteine Combined with Home Based Physical Activity: Effect on Health Related Quality of Life in Stable COPD Patients- A Randomised Controlled Trial.
Salve VT; Atram JS
J Clin Diagn Res; 2016 Dec; 10(12):OC16-OC19. PubMed ID: 28208905
[TBL] [Abstract][Full Text] [Related]
38. N-acetylcysteine protects murine alveolar type II cells from cigarette smoke injury in a nuclear erythroid 2-related factor-2-independent manner.
Messier EM; Day BJ; Bahmed K; Kleeberger SR; Tuder RM; Bowler RP; Chu HW; Mason RJ; Kosmider B
Am J Respir Cell Mol Biol; 2013 May; 48(5):559-67. PubMed ID: 23492188
[TBL] [Abstract][Full Text] [Related]
39. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits.
Rushworth GF; Megson IL
Pharmacol Ther; 2014 Feb; 141(2):150-9. PubMed ID: 24080471
[TBL] [Abstract][Full Text] [Related]
40. High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial.
Johnson K; McEvoy CE; Naqvi S; Wendt C; Reilkoff RA; Kunisaki KM; Wetherbee EE; Nelson D; Tirouvanziam R; Niewoehner DE
Int J Chron Obstruct Pulmon Dis; 2016; 11():799-807. PubMed ID: 27143871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
